FDA Withdraws Kratom and Psychedelics Study Amid Criticism
The FDA has unexpectedly withdrawn its request for a study on kratom and psychedelics, facing criticism for its methodology and potential bias against harm reduction strategies.
Kratom, a Southeast Asian tree with opiate-like properties, is used for pain, anxiety, and opioid withdrawal. Despite its popularity, the FDA has not approved any use of kratom.
The proposed study, which aimed to understand the risks and benefits of kratom and psychedelics, drew criticism from the American Kratom Association and other stakeholders. Critics argued that the FDA's approach was biased and intended to validate predetermined outcomes.
The FDA's withdrawal of the study request comes amidst growing public interest and scientific research into the potential benefits of kratom and psychedelics. Advocates see this move as a victory against what they perceive as unwarranted regulatory overreach.
While the FDA has not provided specific reasons for the withdrawal, it leaves questions about the future of kratom and psychedelic research in the U.S.